Defense mechanisms of Pseudomonas aeruginosa and Klebsiella pneumoniae clinical strains against lytic phages and counter-defense
Year: 2026
Type: article
Abstract: Pseudomonas aeruginosa and Klebsiella pneumoniae are major Gram-negative pathogens in which the emergence of multidrug-resistant strains has increased the need for alternative antimicrobial strategies, including phage therapy. However, bacterial antiphage defense systems and the corresponding phage-encoded counter-defense mechanisms can critically influence phage infectivity and therapeutic potential. Here, we characterized bacterial defense systems in 75 clinical P. aeruginosa and 47 K. pneumoniae isolates and analyzed anti-defense repertoires in collections of 13 and 11 corresponding lytic phages, respectively. Abortive infection (Abi) systems were the predominant characterized defense category in P. aeruginosa , whereas systems of unknown function were the most abundant in K. pneumoniae . Among P. aeruginosa phages, DEDDh_I_II_III_IV_V_VI_1, a DnaQ-like exonuclease associated with anti-CRISPR activity, was the most frequently detected anti-defense determinant (76.92%). In K. pneumoniae phages, stp (anti-restriction) was detected in 54.55% and acb1/acb2 (anti-CBASS) in 27.27%. Phage–host interaction analysis revealed substantial heterogeneity in infectivity and showed that the presence or number of anti-defense systems alone did not consistently predict infection outcome. To investigate the functional contribution of specific anti-defense mechanisms, time-kill assays were performed against P. aeruginosa PA14 and CECT-110 and K. pneumoniae ATCC 700721, and bacterial growth inhibition was quantified from the area under the growth curve (AUC). Notably, anti-CBASS-positive P. aeruginosa phages showed significantly greater growth inhibition than anti-CBASS-negative phages (65.28% vs. 15.77%; difference, 49.51 percentage points; P = 0.0007), whereas no significant association was observed in K. pneumoniae . No significant association with growth inhibition was identified for the other anti-defense categories evaluated. Based on this genotype–phenotype association, we designed a LAMP–CRISPR-Cas13a assay targeting queC (CBASS_associated defense) as a proof of concept for rapid detection of CBASS-associated determinants in P. aeruginosa . Although validation in larger bacterial and phage collections is required, our findings support the integration of bacterial defense profiling with complementary phage anti-defense characterization as a potential strategy for prioritizing candidate phages for subsequent phenotypic evaluation and rational phage therapy.
Source: Scientific Reports
Authors: Lucía Armán, Lucía Blasco, Inés Blériot, Laura Fernández-García, Zuzanna Drulis-Kawa, Agata Dorotkiewicz-Jach, Ran Nir-Paz, Jean-Paul Pirnay, Sabrina Green, Rob Lavigne, Rafael Cantón, Antonio Oliver, Maria Pérez Vázquez, María Tomás, Enrique Cañada-Garcia, Jesús Oteo-Iglesias, Hannah Morelli, Evelien Adriaenssens
Institutions: Universidade da Coruña, European Society of Clinical Microbiology and Infectious Diseases, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, University of Wrocław, Hebrew University of Jerusalem, Hadassah Medical Center, Queen Astrid Military Hospital, KU Leuven, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Centro Nacional de Microbiologia, Quadram Institute
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
Awards: Evolución, diagnóstico y tratamiento de patógenos multiresistentes a los antimicrobianos (RAM):Revolución CRISPR-Cas (RAM-CRISPR), G4987700822, G524855180, G5867013586, G683903339, G7096929632, La medicina de precisión contra la resistencia a antimicrobianos: Proyecto MePRAM, Desarrollo de Infraestructuras ISCIII para la creación, estandarización y producción de fagos útiles en Infecciones bacterianas pulmonares crónicas. (DISCIII-Phage)
OpenAlex ID: W7218858776
